{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:45:36Z","timestamp":1790891136479,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"am","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.humpath.2025.105812","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T23:07:57Z","timestamp":1747782477000},"page":"105812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing"],"prefix":"10.1016","volume":"159","author":[{"given":"Yuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinchita","family":"Roy-Chowdhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Czerniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-3287","authenticated-orcid":false,"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2025.105812_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","article-title":"Bladder cancer in the genomic era","volume":"143","author":"Guo","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2025.105812_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.path.2022.07.004","article-title":"Molecular taxonomy and immune checkpoint therapy in bladder cancer","volume":"15","author":"Guo","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.humpath.2025.105812_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.5858\/2006-130-844-DPOBCP","article-title":"Dual-track pathway of bladder carcinogenesis: practical implications","volume":"130","author":"Spiess","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2025.105812_bib4","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.humpath.2025.105812_bib5","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"22","author":"Amin","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology (Oxf)"},{"key":"10.1016\/j.humpath.2025.105812_bib7","series-title":"Urinary and male genital tumours","author":"Board","year":"2022"},{"key":"10.1016\/j.humpath.2025.105812_bib8","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/00000478-199412000-00005","article-title":"Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma","volume":"18","author":"Amin","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e3181ec86b3","article-title":"Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists","volume":"34","author":"Sangoi","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.humpath.2012.04.013","article-title":"Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases","volume":"43","author":"Amin","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00428-016-1986-x","article-title":"Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy","volume":"469","author":"Bertz","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2025.105812_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0022-5347(05)00423-4","article-title":"The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma","volume":"175","author":"Kamat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.humpath.2025.105812_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2025.105812_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2025.105812_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2025.105812_bib16","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.humpath.2025.105812_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2025.105812_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2025.105812_bib19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/modpathol.2011.69","article-title":"HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization","volume":"24","author":"Ching","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","article-title":"Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma","volume":"4","author":"Behzato\u011flu","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.humpath.2025.105812_bib21","first-page":"205","article-title":"Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder","volume":"10","author":"Sanguedolce","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.humpath.2025.105812_bib22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2025.105812_bib23","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2025.105812_bib24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.humpath.2025.105812_bib25","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","article-title":"Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer","volume":"27","author":"Guo","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.humpath.2025.105812_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-Neural plasticity drives progression to small cell bladder cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.humpath.2025.105812_bib27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.humpath.2014.02.023","article-title":"Differential expression of GATA-3 in urothelial carcinoma variants","volume":"45","author":"Liang","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-017-2190-3","article-title":"FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma","volume":"471","author":"Warrick","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2025.105812_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"Zinnall","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11523-024-01056-x","article-title":"Frequency and nature of genomic alterations in ERBB2-altered urothelial bladder cancer","volume":"19","author":"Leary","year":"2024","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.humpath.2025.105812_bib31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2025.105812_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humpath.2025.105812_bib33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/modpathol.2013.201","article-title":"Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome","volume":"27","author":"Schneider","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100424","article-title":"Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2","volume":"37","author":"Posada","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/biom9100629","article-title":"The HER2 S310F mutant can form an active heterodimer with the EGFR, which can Be inhibited by cetuximab but not by trastuzumab as well as pertuzumab","volume":"9","author":"Shin","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.humpath.2025.105812_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.humpath.2025.105812_bib37","article-title":"Advances in HER2-targeted treatment for advanced\/metastatic urothelial carcinoma","volume":"10","author":"Qu","year":"2023","journal-title":"Bladder (San Franc)"},{"key":"10.1016\/j.humpath.2025.105812_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.humpath.2025.105812_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib41","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105812_bib42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","article-title":"Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes","volume":"53","author":"Takahara","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2025.105812_bib43","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1111\/cas.14672","article-title":"CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression","volume":"111","author":"Yanai","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2025.105812_bib44","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1111\/jcmm.17512","article-title":"Interaction between HER2 and ATM predicts poor survival in bladder cancer patients","volume":"26","author":"Albarakati","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.humpath.2025.105812_bib45","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1634\/theoncologist.2018-0845","article-title":"Emergence of ERBB2 mutation as a biomarker and an actionable target in Solid cancers","volume":"24","author":"Subramanian","year":"2019","journal-title":"Oncologist"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T08:29:03Z","timestamp":1749284943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"alternative-id":["S0046817725000991"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105812","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular profile of micropapillary urothelial carcinoma of the urinary bladder: An analysis of 99 cases by next-generation sequencing","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105812"}}